January 1, 2011 Journal article Open Access

Barak; Paola Ferrari; Angelo Carpi; Andrea Nicolini; Paolo Miccoli; Massimo Conte; Michael J. Duffy; Giorgio Rossi

DataCite XML Export

<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://datacite.org/schema/kernel-4" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd">
  <identifier identifierType="URL">https://www.openaccessrepository.it/record/119229</identifier>
  <creators>
    <creator>
      <creatorName>Barak</creatorName>
    </creator>
    <creator>
      <creatorName>Paola Ferrari</creatorName>
    </creator>
    <creator>
      <creatorName>Angelo Carpi</creatorName>
    </creator>
    <creator>
      <creatorName>Andrea Nicolini</creatorName>
    </creator>
    <creator>
      <creatorName>Paolo Miccoli</creatorName>
    </creator>
    <creator>
      <creatorName>Massimo Conte</creatorName>
    </creator>
    <creator>
      <creatorName>Michael J. Duffy</creatorName>
    </creator>
    <creator>
      <creatorName>Giorgio Rossi</creatorName>
    </creator>
  </creators>
  <titles>
    <title>Additional 5-FU-LV significantly increases survival in gastrointestinal cancer.</title>
  </titles>
  <publisher>INFN Open Access Repository</publisher>
  <publicationYear>2011</publicationYear>
  <subjects>
    <subject>General Immunology and Microbiology</subject>
    <subject>General Biochemistry, Genetics and Molecular Biology</subject>
  </subjects>
  <dates>
    <date dateType="Issued">2011-01-01</date>
  </dates>
  <language>en</language>
  <resourceType resourceTypeGeneral="Text">Journal article</resourceType>
  <alternateIdentifiers>
    <alternateIdentifier alternateIdentifierType="url">https://www.openaccessrepository.it/record/119229</alternateIdentifier>
  </alternateIdentifiers>
  <relatedIdentifiers>
    <relatedIdentifier relatedIdentifierType="DOI" relationType="IsIdenticalTo">10.2741/e348</relatedIdentifier>
    <relatedIdentifier relatedIdentifierType="URL" relationType="IsPartOf">https://www.openaccessrepository.it/communities/itmirror</relatedIdentifier>
  </relatedIdentifiers>
  <rightsList>
    <rights rightsURI="info:eu-repo/semantics/openAccess">Open Access</rights>
  </rightsList>
  <descriptions>
    <description descriptionType="Abstract">Metastatic colorectal and other locally advanced gastrointestinal (G.I.) cancers often recur after curative resection. Many mechanisms of tumor growth and/or immune escape by residual cancer cells may provoke tumor progression. Long-term, cytostatic action with repeated post-adjuvant administration of 5-fluorouracil (FU)-leucovorin (LV) cycles may interrupt or downregulate these mechanisms and favor the recovery and/or increase the immune system activity. Seventy patients were considered. An active prospective cohort including 21 patients (study group) was matched in a 1:1 ratio with a retrospective parallel control group of 21 patients. The study group received long-term repeated post-adjuvant administration of 5-FU-LV cycles, while the matched control group was conventionally treated. Statistical analysis was performed by Kaplan-Meier method and Cox's proportional hazard regression model. The five-year disease-free survival (DFS) was 77.0 + 10.1 % and 31.7 + 10.6 % (p = 0.001; hazard ratio (HR) 5.3, 95 % C.I.: 1.7-16.1, p = 0.003), while the five-year overall survival (OS) was 88.0 + 8.1 % and 37.0 + 10.7 % (p = 0.001; HR 8.9, 95 % C.I.: 2.0-39.9, p = 0.004) in the study group and in matched controls respectively. These findings suggest a relevant improvement in the outcome of this population by an intermittent and prolonged cytostatic effect with 5-FU-LV.</description>
  </descriptions>
</resource>